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Purpose of the study
Lersivirine (UK-453,051), a new potent NNRTI, displays
novel binding with a unique in vitro resistance profile,
and shows potential for use against transmitted NNRTI
resistant virus and as a candidate for sequential NNRTI
therapy. Further in vitro analyses have been performed
to establish the breadth of activity and identify potential
populations that might benefit from lersivirine therapy.
Lersivirine activity against various HIV-1 subtypes and
viruses with decreased susceptibility to etravirine (ETR)
were characterised.
Methods
The PhenoSense™ assay was used to assess the antiviral
activity of lersivirine against different HIV-1 subtypes
( A ,A 1 ,B ,B F ,C ,C / H ,D ,F ,F 1 ,Ga n dH ) ,a n dt h ec i r -
culating recombinant forms (CRFs) CRF01_AE and
CRF02_AG. All were obtained from treatment-naïve
patients. Nineteen additional clinical viruses with
NNRTI resistance associated mutations (RAMs) were
selected based on their reduced susceptibility to ETR.
Summary of results
Lersivirine was active against a panel of 80 clinically-
derived viruses representing subtypes A to H, including
several CRFs, from a range of geographical origins (geo-
metric mean IC50 fold change [FC] to reference virus
was 0.92). IC50 FC were < 2 for all viruses with the
exception of 1 subtype BF and 1 subtype C (geometric
mean IC50 FC: subtype BF = 0.98, 95% CI 0.64 - 1.49,
n=7; subtype C = 1.07, 95% CI 0.88 - 1.30, n=25). Lersi-
virine retained activity (< 10 FC IC50) for 11 of the 19
viruses with ETR resistance (> 2.9 FC IC50, lower clini-
cal cut-off). Overall, a direct correlation between lersi-
virine and ETR susceptibility was not found (R
2 =
0.002). This is consistent with different genotypic resis-
tance profiles. Indeed to date, reduced susceptibility to
lersivirine and ETR is associated with the presence of
different specific NNRTI RAMs.
Conclusions
Lersivirine showed comparable activity across a range of
viruses representing subtypes A to H. The activity of ler-
sivirine against ETR- resistant viruses reflects significant
differences in the resistance profiles of lersivirine and
ETR consistent with the unique binding of lersivirine in
the NNRTI binding pocket. Lersivirine has a distinctive
in vitro resistance profile and may provide an additional
therapy choice for patients with evidence of NNRTI
resistance.
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